Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win

Intelligent Bio Solutions Inc. INBS recently announced that it has secured a key patent in the United States relating to the Intelligent Fingerprinting Drug Screening Cartridge. This is the company’s sixth active patent to be granted in the United States, strengthening the protection of its unique and proprietary drug screening technology.With this strategic milestone, INBS aims to enhance its competitive edge in the industry while accelerating the commercialization of the technology. As the company moves closer to market launch, the strengthened intellectual property (“IP”) protection underscores confidence in its product's potential impact.Likely Trend of INBS Stock Following the NewsFollowing the announcement, shares of the company tumbled 5.1% and closed at $1.67 yesterday. In the past six months, INBS’ shares have lost 8.2% compared with the industry’s 13.2% decline. The S&P 500 improved 1% in the same time frame.However, securing a key U.S. patent strengthens INBS’ competitive edge by protecting its proprietary technology, reducing the risk of imitation and reinforcing investor confidence in long-term growth potential. This milestone enhances the company’s positioning ahead of its 2025 drug screening market entry, increasing the likelihood of successful commercialization and potential partnerships. As demand for innovative biometric diagnostic solutions rises, a strong IP portfolio can attract institutional investors, improve market perception and drive sustainable revenue growth, ultimately boosting the performance of the INBS stock over time.Meanwhile, INBS currently has a market capitalization of $11.9 billion. The company expects an earnings growth of 80.4% in 2025.Image Source: Zacks Investment ResearchMore on INBS’ Intelligent Fingerprinting Drug Screening CartridgeINBS has developed a robust IP portfolio to safeguard its innovative drug screening technology. The company has been granted six active U.S. patents, each covering distinct aspects of its Intelligent Fingerprinting Drug Screening System. These patents encompass the proprietary lateral flow test strip within the Drug Screening Cartridge, the Sample Collection Cartridge, the cartridge housing and the buffer clip design. This comprehensive IP protection reinforces INBS' competitive position as it prepares to enter the U.S. drug screening market in 2025.INBS’ Intelligent Fingerprinting Drug Screening Cartridge is a cutting-edge, non-invasive drug testing solution, designed to detect drug metabolites through fingerprint sweat analysis. Unlike traditional urine or blood tests, this innovative approach offers rapid, hygienic and user-friendly screening, making it ideal for workplace testing, law enforcement, rehabilitation programs and clinical applications.The cartridge works by collecting a small sweat sample from a fingerprint, which is then analyzed using INBS’ portable reader, delivering results in minutes. This method eliminates the need for invasive sample collection, reducing the risk of contamination, tampering or privacy concerns often associated with conventional drug testing. Additionally, the compact and portable design enhances accessibility, allowing for on-the-spot testing in various environments.Favorable Industry Prospects for INBSPer a report by Marketsandmarkets, the global drug screening market was valued at $7.7 billion in 2023 and is forecasted to grow at a robust CAGR of 16.6%, reaching an impressive $19.5 billion by 2029. INBS is poised to tap into the $19.5 billion drug screening market with its patented, non-invasive and rapid fingerprint drug test.INBS’ Zacks Rank & Stocks to ConsiderINBS carries a Zacks Rank #3 (Hold) at present.Some better-ranked stocks in the broader medical space are Masimo MASI, Boston Scientific BSX and Cardinal Health CAH. At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.Masimo’s shares have rallied 30.1% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have gained 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intelligent Bio Solutions Inc. (INBS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks